Pyxis Oncology, Inc. (PYXS) 10-Year Financial Performance & Capital Metrics

PYXS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutPyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $16M
EBITDA -$86M -7.7%
Net Income -$77M -4.8%
EPS (Diluted) -1.32 +28.6%
Gross Margin 97.06%
EBITDA Margin -535.6%
Operating Margin -554.07%
Net Margin -478.95%
ROE -62.75% -21.8%
ROIC -51.84% +42.1%
Debt/Equity 0.17 -1.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.9x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 46.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-82.53%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-69.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.98%

ROCE

10Y Avg-56.09%

5Y Avg-64.29%

3Y Avg-56.13%

Latest-62.24%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	16.15M
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	444K	0	0	0	475K
COGS % of Revenue	-	-	-	-	-	0.03%
Gross Profit+	0	-444K	0	0	0	15.67M
Gross Margin %	-	-	-	-	-	0.97%
Gross Profit Growth %	-	-	1%	-	-	-
Operating Expenses+	2.88M	12.45M	69.72M	123.48M	82.2M	105.13M
OpEx % of Revenue	-	-	-	-	-	6.51%
Selling, General & Admin	1.66M	3.85M	18.66M	37.35M	32.61M	25.42M
SG&A % of Revenue	-	-	-	-	-	1.57%
Research & Development	1.22M	8.6M	51.05M	86.13M	49.59M	58.75M
R&D % of Revenue	-	-	-	-	-	3.64%
Other Operating Expenses	0	0	0	0	0	20.96M
Operating Income+	-2.88M	-12.89M	-69.72M	-123.48M	-82.2M	-89.46M
Operating Margin %	-	-	-	-	-	-5.54%
Operating Income Growth %	-	-3.48%	-4.41%	-0.77%	0.33%	-0.09%
EBITDA+	-2.77M	-12.45M	-69.07M	-122.77M	-80.27M	-86.48M
EBITDA Margin %	-	-	-	-	-	-5.36%
EBITDA Growth %	-	-3.49%	-4.55%	-0.78%	0.35%	-0.08%
D&A (Non-Cash Add-back)	0	444K	647K	709K	1.93M	2.98M
EBIT	-2.77M	-12.83M	-69.72M	-123.48M	-82.2M	-68.5M
Net Interest Income+	107K	66K	23K	2.76M	6.63M	7.04M
Interest Income	107K	66K	23K	2.76M	6.63M	7.04M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	107K	66K	-6.26M	2.76M	8.41M	9.96M
Pretax Income+	-2.77M	-12.83M	-75.97M	-120.72M	-73.79M	-79.5M
Pretax Margin %	-	-	-	-	-	-4.92%
Income Tax+	0	0	0	0	0	-2.16M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.97%
Net Income+	-2.77M	-12.83M	-75.97M	-120.72M	-73.79M	-77.33M
Net Margin %	-	-	-	-	-	-4.79%
Net Income Growth %	-	-3.63%	-4.92%	-0.59%	0.39%	-0.05%
Net Income (Continuing)	-2.77M	-12.83M	-75.97M	-120.72M	-73.79M	-77.33M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.37	-2.53	-3.57	-1.85	-1.32
EPS Growth %	-	-3.76%	-5.84%	-0.41%	0.48%	0.29%
EPS (Basic)	-0.08	-0.37	-2.53	-3.57	-1.85	-1.32
Diluted Shares Outstanding	34.31M	34.31M	32.22M	33.03M	39.9M	58.45M
Basic Shares Outstanding	34.31M	34.31M	32.22M	33.03M	39.9M	58.45M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	19.7M	8.1M	278.67M	186.61M	124.6M	132.44M
Cash & Short-Term Investments	19.69M	8.08M	274.74M	179.29M	119.3M	126.93M
Cash Only	19.69M	8.08M	274.74M	179.29M	9.66M	19.47M
Short-Term Investments	0	0	0	0	109.63M	107.46M
Accounts Receivable	0	0	0	598K	21K	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	15K	1.56M	5.41M	4.27M	4.75M
Total Non-Current Assets+	106K	2.05M	1.35M	24.77M	49.12M	24.74M
Property, Plant & Equipment	76K	1.94M	1.24M	24.77M	24.81M	22.14M
Fixed Asset Turnover	-	-	-	-	-	0.73x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	24.31M	2.6M
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	30K	109K	109K	0	0	0
Total Assets+	19.81M	10.15M	280.02M	211.38M	173.73M	157.18M
Asset Turnover	-	-	-	-	-	0.10x
Asset Growth %	-	-0.49%	26.59%	-0.25%	-0.18%	-0.1%
Total Current Liabilities+	733K	3.69M	18.71M	31.63M	25.76M	17.68M
Accounts Payable	491K	1.08M	11.95M	7.1M	3.9M	4.86M
Days Payables Outstanding	-	885.37	-	-	-	3.73K
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	1000K	0
Other Current Liabilities	116K	1.12M	3.23M	5.33M	5.58M	4.63M
Current Ratio	26.88x	2.20x	14.90x	5.90x	4.84x	7.49x
Quick Ratio	26.88x	2.20x	14.90x	5.90x	4.84x	7.49x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	21.95M	22.11M	0	18.92M	22.26M	18.75M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	6K	165K	0	18.92M	20.1M	18.75M
Deferred Tax Liabilities	0	0	0	0	2.16M	0
Other Non-Current Liabilities	21.94M	21.94M	0	0	0	0
Total Liabilities	22.68M	25.8M	18.71M	50.55M	48.02M	36.43M
Total Debt+	15K	780K	165K	18.92M	21.33M	20.2M
Net Debt	-19.68M	-7.3M	-274.57M	-160.37M	11.67M	727K
Debt / Equity	-	-	0.00x	0.12x	0.17x	0.17x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-2.87M	-15.64M	261.31M	160.82M	125.7M	120.75M
Equity Growth %	-	-4.44%	17.7%	-0.38%	-0.22%	-0.04%
Book Value per Share	-0.08	-0.46	8.11	4.87	3.15	2.07
Total Shareholders' Equity	-2.87M	-15.64M	261.31M	160.82M	125.7M	120.75M
Common Stock	1K	1K	32K	34K	45K	60K
Retained Earnings	-2.92M	-15.74M	-91.72M	-212.44M	-286.23M	-363.56M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	63K	170K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.24M	-10.08M	-35.33M	-89.33M	-70.71M	-57.67M
Operating CF Margin %	-	-	-	-	-	-3.57%
Operating CF Growth %	-	-3.5%	-2.5%	-1.53%	0.21%	0.18%
Net Income	-2.77M	-12.83M	-75.97M	-120.72M	-73.79M	-77.33M
Depreciation & Amortization	0	469K	647K	709K	1.93M	2.98M
Stock-Based Compensation	28K	44K	6.44M	15.76M	16.95M	12.95M
Deferred Taxes	0	0	6.28M	0	0	0
Other Non-Cash Items	-264K	-56K	20.6M	10.41M	-4.13M	15.55M
Working Capital Changes	505K	2.29M	6.68M	4.5M	-11.66M	-11.82M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	292K	558K	4.64M	-8.33M	-3.51M	1.2M
Cash from Investing+	0	-1.48M	-590K	-6.4M	-104.85M	8.15M
Capital Expenditures	0	-1.48M	-540K	-6.4M	-6.73M	-237K
CapEx % of Revenue	-	-	-	-	-	0.01%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-50	0	0	0
Cash from Financing+	21.95M	35K	304.04M	183K	5.93M	59.33M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	21.95M	32K	167K	183K	-193K	280K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.24M	-11.57M	-35.87M	-95.73M	-77.44M	-57.91M
FCF Margin %	-	-	-	-	-	-3.59%
FCF Growth %	-	-4.17%	-2.1%	-1.67%	0.19%	0.25%
FCF per Share	-0.07	-0.34	-1.11	-2.90	-1.94	-0.99
FCF Conversion (FCF/Net Income)	0.81x	0.79x	0.46x	0.74x	0.96x	0.75x
Interest Paid	0	0	0	0	1K	10K
Taxes Paid	0	0	0	17K	48K	164K

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-61.85%	-57.19%	-51.51%	-62.75%
Return on Invested Capital (ROIC)	-	-	-	-	-89.46%	-51.84%
Gross Margin	-	-	-	-	-	97.06%
Net Margin	-	-	-	-	-	-478.95%
Debt / Equity	-	-	0.00x	0.12x	0.17x	0.17x
FCF Conversion	0.81x	0.79x	0.46x	0.74x	0.96x	0.75x

Frequently Asked Questions

Growth & Financials

Pyxis Oncology, Inc. (PYXS) reported $2.8M in revenue for fiscal year 2024.

Pyxis Oncology, Inc. (PYXS) grew revenue by 0.0% over the past year. Growth has been modest.

Pyxis Oncology, Inc. (PYXS) reported a net loss of $97.1M for fiscal year 2024.

Dividend & Returns

Pyxis Oncology, Inc. (PYXS) has a return on equity (ROE) of -62.8%. Negative ROE indicates the company is unprofitable.

Pyxis Oncology, Inc. (PYXS) had negative free cash flow of $72.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener